From Scorpion Venom to Infection Research: The Promise of Opis16a (Blog Entry)

Posted by
  Opistophthalmus carinatus , a southern African scorpion whose venom contains opistoporin 1, the parent peptide from which researchers derived the shorter antimicrobial peptide Opis16a. Credit: Dan Lee / CC0 1.0 From Scorpion Venom to Infection Research: The Promise of Opis16a A synthetic peptide inspired by a southern African scorpion’s venom shows activity against drug-resistant bacteria—but its potential as a wound treatment remains under investigation. Scorpion venom is a complex mixture of biologically active molecules. While many are studied for their effects on ion channels and the nervous system, others offer a different research opportunity: understanding how peptides can damage bacterial cells. One such candidate is Opis16a , a synthetic, 16-amino-acid fragment derived from opistoporin 1, a peptide originally isolated from the venom of Opistophthalmus carinatus . Research highlighted by Nature Africa suggests that this shortened molecule combines broad antibacterial acti...

Low-dose versus standard-dose antivenom for neuroparalytic krait envenomation: a randomized pilot study

Posted by

 

Image Credit: By Jayendra Chiplunkar - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=17650765

Low-dose versus standard-dose antivenom for neuroparalytic krait envenomation: a randomized pilot study

Abstract

Introduction

The common krait (Bungarus caeruleus) is a leading cause of neuroparalytic snake envenomation in South Asia. Current guidelines recommend escalation from 10 to 20 vials of polyvalent antivenom if neurotoxicity persists, despite limited evidence supporting this strategy.

Methods

This open-label, randomized pilot study was conducted in North India, enrolling patients with krait envenomation who presented with neurotoxic paralysis but without respiratory failure. Patients were assigned to receive either 10 vials or 20 vials of polyvalent antivenom. The primary outcome was time to recovery from neurotoxic paralysis. Secondary outcomes included the need for invasive mechanical ventilation, time from enrolment to intubation, duration of mechanical ventilation, and in-hospital mortality.

Results

Of 97 patients screened, 53 underwent randomization (26 assigned to the 10-vial group and 27 to the 20-vial group). Baseline characteristics, severity of neurotoxic paralysis, laboratory parameters, and time from bite to enrolment (median 5 hours) were similar between groups. The median time to recovery from neurotoxic paralysis was 42.5 hours (IQR, 29.8–54.3) in the 10-vial group and 45.0 hours (IQR, 35.5–59.5) in the 20-vial group (median difference, −5.0 hours; 95% CI, −15.5 to 5.5; P = 0.24); Kaplan–Meier analysis showed no significant between-group difference (log-rank P = 0.38). Invasive mechanical ventilation was required in 34.6% of patients in the 10-vial group and 22.2% in the 20-vial group (risk ratio, 1.34; 95% CI, 0.77 to 2.31). Among ventilated patients, the median time to intubation and duration of mechanical ventilation were similar between groups. One death occurred in the 10-vial group.

Discussion

Routine escalation of antivenom dosing may not be necessary in krait neurotoxicity with close respiratory monitoring and supportive care.

Conclusions

Among patients with neuroparalytic krait envenomation who presented without respiratory failure, a 10-vial antivenom regimen was associated with clinical outcomes comparable to those with a 20-vial regimen.


Jyothika, S., Mathen, P. G., Sharma, R., Singla, N., Sharma, N., & Pannu, A. K. (2026). Low-dose versus standard-dose antivenom for neuroparalytic krait envenomation: a randomized pilot study. Clinical Toxicology, 1–8. https://doi.org/10.1080/15563650.2026.2655938